J Cancer 2019; 10(11):2407-2414. doi:10.7150/jca.32411 This issue


The Advancement of Long Non-Coding RNAs in Cholangiocarcinoma Development

Fengru Jiang, Xiaofeng Ling

Department of General Surgery, Peking University Third Hospital, 49 North Garden Rd., Haidian District Beijing, P.R.China, 100191, 86-010-82267332

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Jiang F, Ling X. The Advancement of Long Non-Coding RNAs in Cholangiocarcinoma Development. J Cancer 2019; 10(11):2407-2414. doi:10.7150/jca.32411. Available from https://www.jcancer.org/v10p2407.htm

File import instruction


Cholangiocarcinoma (CCA) is a malignancy with increasing incidence in recent years. CCA patients are usually diagnosed at advanced stage due to lack of apparent symptoms and specifically diagnostic markers. Nowadays, surgical removal is the only effective method for CCA whereas overall 5-year-survival rate keeps around 10%. Long-noncoding RNA (lncRNA), a subtype of noncoding RNA, is widely studied to be abnormally expressed in multiple cancers including CCA. LncRNA can promote proliferation, migration, invasion and inhibit apoptosis of CCA. Moreover, lncRNA is negatively correlated with the prognosis of CCA. LncRNA may contribute to the development of CCA via modulating gene transcription, sponging microRNA, regulating CCA-related signaling pathways or protein expression. LncRNA is thought to be potential diagnostic markers and therapeutic targets for CCA.

Keywords: cholangiocarcinoma, lncRNA, proliferation, invasion, prognosis